Who
Paul T. Quinlan
General Counsel
Company insider
Files Form 4 as: General Counsel, Oruka Therapeutics; General Counsel, CymaBay Therapeutics; General Counsel, TerraVia Holdings.
In numbers
- Trades disclosed
- 217
- Buys
- 0
- Sells
- 57
- Bought
- $0
- Sold
- $17.5M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 12 Jan 2012
- Last trade
- 20 Oct 2026
- Last filed
- 20 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Oct 2026filed 20 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $70K9,000 at $7.80 | filing |
| 20 Oct 2026filed 20 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K400 at $74.90 | filing |
| 20 Oct 2026filed 20 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $38K500 at $76.12 | filing |
| 20 Oct 2026filed 20 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $77K1,000 at $77.21 | filing |
| 20 Oct 2026filed 20 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $323K4,100 at $78.79 | filing |
| 20 Oct 2026filed 20 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $238K3,000 at $79.49 | filing |
| 20 Oct 2026filed 20 Oct 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,000 at $0.00 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $78K10,000 at $7.80 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $268K2,900 at $92.37 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $358K3,832 at $93.32 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $57K601 at $94.44 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $254K2,667 at $95.31 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $78K10,000 at $7.80 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $268K2,900 at $92.37 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $358K3,832 at $93.32 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $57K601 at $94.44 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $254K2,667 at $95.31 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $99K1,039 at $95.71 | filing |
News
No headline names them, or the companies they trade most, lately.